| Humalog pen (insulin lispro) / Eli Lilly |
NCT00311077: Insulin Glulisine in Healthy Lean and Obese Subjects |
|
|
| Completed | 1 | | Europe | Insulin Glulisine | Sanofi | Diabetes Mellitus | 10/04 | | | |
NCT00705536: Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 |
|
|
| Completed | 1 | 26 | US | Humalog, Insulin lispro, Humulin-R, Humulin, Recombinant human insulin, Recombinant human hyaluronidase PH20 (rHuPH20), PH20, HYLENEX | Halozyme Therapeutics | Diabetes Mellitus | 02/08 | 02/08 | | |
| Completed | 1 | 30 | Europe | Levemir, Insulin Detemir, Humalog NPL Insulin, Humalog NPL | Medical University of Graz | Diabetes, Type I | 12/08 | 12/08 | | |
NCT00862849: Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone |
|
|
| Completed | 1 | 22 | US | Insulin Lispro, Humalog, Regular Human Insulin, RHI, Humulin R, rHuPH20, recombinant human hyaluronidase, HYLENEX | Halozyme Therapeutics | Diabetes Mellitus | 06/09 | 08/09 | | |
NCT00803972: Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 |
|
|
| Completed | 1 | 42 | US | rHuPH20, Insulin Human Injection, Humulin® R, Insulin Lispro Injection, Humalog® | Halozyme Therapeutics | Healthy Volunteers | 08/09 | 08/09 | | |
NCT00979875: A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone |
|
|
| Completed | 1 | 14 | US | Recombinant human hyaluronidase PH20 (rHuPH20), HYLENEX, PH20, Insulin lispro, Humalog, Lispro, Insulin glulisine, Apidra, Glulisine, Insulin aspart, NovoLog, Aspart | Halozyme Therapeutics | Healthy | 02/10 | 05/10 | | |
| Completed | 1 | 41 | RoW | Insulin lispro A, LY275585, Insulin lispro B | Eli Lilly and Company | Healthy Volunteers | 08/10 | 08/10 | | |
NCT01201278: PK/PD Study of Intranasal Insulin in Type I Diabetes |
|
|
| Unknown status | 1 | 20 | US | Insulin, Insulin LISPRO | Hompesch, Marcus, M.D., Profil Institute for Clinical Research, Inc. | Type 1 Diabetes | | | | |
NCT01334151: Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 13 | US | Insulin LISPRO, recombinant human insulin | Biodel | Diabetes Mellitus Type 1 | 08/11 | 08/11 | | |
NCT00652288: Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs |
|
|
| Completed | 1 | 36 | US | Insulin analogs (Lispro and Aspart), Humalog, Novolog, Insulin analogs (Aspart and Detemir), Insulin analogs (Lispro and Glargine) | Yale University | Diabetes Mellitus, Type I | 09/11 | 09/11 | | |
| Completed | 1 | 37 | US | TAK-329, Insulin, Insulin lispro, Humalog, Placebo | Takeda | Type 1 Diabetes Mellitus | 12/11 | 01/12 | | |
NCT01908894: Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration |
|
|
| Completed | 1 | 12 | US | BIOD-123, BIOD-125, Humalog | Biodel | Diabetes Mellitus | 03/12 | 03/12 | | |
NCT01399255: Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects |
|
|
| Withdrawn | 1 | 0 | US | Insulin lispro, Listro™ and Humalog® | Wockhardt | Bioequivalence in Healthy Subjects | 05/12 | 06/12 | | |
NCT01638325: A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants |
|
|
| Completed | 1 | 37 | RoW | Insulin Lispro, Humalog, LY275585, BC106 insulin lispro, BioChaperone insulin lispro | Adocia, Eli Lilly and Company | Healthy Participants | 09/12 | 09/12 | | |
NCT01811849: Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 12 | RoW | Insulin LISPRO | Biodel | Type 1 Diabetes | 12/12 | 12/12 | | |
|
NCT02273258: A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 30 | Europe | SAR342434, Insulin Lispro | Sanofi | Type 1 Diabetes | 07/13 | 07/13 | | |
NCT01871493: A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants |
|
|
| Completed | 1 | 40 | RoW | LY2605541, Insulin Lispro, Humalog | Eli Lilly and Company | Healthy Volunteers | 09/13 | 09/13 | | |
NCT02029924: A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 37 | Europe | BioChaperone insulin lispro, Humalog® | Adocia | Diabetes Mellitus Type 1 | 03/14 | 08/14 | | |
NCT02131948: Regulation of Endogenous Glucose Production by Brain Insulin Action |
|
|
| Completed | 1 | 8 | Canada | Intranasal insulin, Humalog lispro 40 IU intranasally, Intranasal placebo, Diluent intranasally | University Health Network, Toronto | Insulin Resistance, Diabetes | 07/14 | 07/14 | | |
NCT02317575: A Study of LY900014 Formulations in Healthy Participants |
|
|
| Completed | 1 | 29 | RoW | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585 | Eli Lilly and Company | Healthy Volunteers | 04/15 | 09/15 | | |
NCT02344992 / 2014-005028-92: Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal |
|
|
| Completed | 1 | 38 | Europe | BioChaperone insulin lispro, Humalog® | Adocia | Diabetes Mellitus Type 1 | 06/15 | 06/15 | | |
NCT02293551: A Study of Lispro Formulations in Healthy Participants |
|
|
| Completed | 1 | 54 | RoW | Lispro, LY275585 | Eli Lilly and Company | Healthy Volunteers | 09/15 | 09/15 | | |
NCT02470637: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 30 | Europe | SAR439065, Afrezza Technosphere insulin, Insulin lispro, Humalog | Mannkind Corporation | Type 1 Diabetes Mellitus | 09/15 | 09/15 | | |
NCT02525744: A Study of a New LY900014 Formulation in Healthy Participants |
|
|
| Completed | 1 | 24 | RoW | LY900014, Ultra-Rapid Lispro, Insulin Lispro (Humalog), LY275585, Humalog | Eli Lilly and Company | Healthy | 10/15 | 10/15 | | |
ACTRN12615001100583: Comparative assessment of the absorption of a generic formulation of Inhaled Insulin against the innovators Humalog KwikPen for injection and the AFREZZA Inhalation Powder Cartridge conducted under fasting conditions in healthy male and female volunteers |
|
|
| Completed | 1 | 18 | | | Zenith Technology Corp Ltd, Cipla Ltd | Pharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied.
Insulin is a medicine that is used to lower blood glucose. | | | | |
NCT02528396: To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 36 | Europe | BioChaperone insulin lispro, Humalog® | Adocia, Eli Lilly and Company | Type 1 Diabetes Mellitus | 12/15 | 12/15 | | |
NCT02562326: A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 51 | Europe | BioChaperone insulin lispro, Humalog® | Adocia, Eli Lilly and Company | Type 2 Diabetes Mellitus | 01/16 | 01/16 | | |
NCT02636361: A Study of Various Formulations of LY900014 in Healthy Participants |
|
|
| Completed | 1 | 26 | RoW | LY900014, Ultra-Rapid Lispro, Insulin lispro (Humalog), Humalog, LY275585 | Eli Lilly and Company | Healthy | 02/16 | 02/16 | | |
NCT02603510: Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion |
|
|
| Completed | 1 | 27 | US | SAR342434, insulin lispro, Humalog | Sanofi | Type 1 Diabetes Mellitus | 04/16 | 04/16 | | |
NCT02660502: An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects |
|
|
| Completed | 1 | 15 | Europe | Biochaperone insulin lispro 0.1 U/kg, Biochaperone insulin lispro 0.2 U/kg, Biochaperone insulin lispro 0.4 U/kg, Humalog® | Adocia, Eli Lilly and Company | Healthy | 05/16 | 05/16 | | |
NCT02703350: A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy |
|
|
| Completed | 1 | 30 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585 | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 07/16 | 07/16 | | |
NCT02703337: A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy |
|
|
| Completed | 1 | 30 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 08/16 | 08/16 | | |
NCT02500979: Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 34 | US | Pramlintide acetate, Pramlintide: SYMLIN, Placebo, Lispro insulin U-100, Humalog insulin lispro U-100, Regular insulin U-100, Humulin R; U-100 | AstraZeneca, Juvenile Diabetes Research Foundation | Type 1 Diabetes Mellitus | 08/16 | 08/16 | | |
NCT02562313: A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® |
|
|
| Completed | 1 | 80 | Europe | BioChaperone insulin lispro, Humalog® | Adocia, Eli Lilly and Company | Type 1 Diabetes Mellitus | 11/16 | 11/16 | | |
NCT03056456: A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump |
|
|
| Completed | 1 | 24 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro (Humalog), LY275585, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 06/17 | 06/17 | | |
NCT03166124: A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 80 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, Humalog, LY275585 | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 11/17 | 11/17 | | |
NCT03305822: A Study of LY900014 in Participants With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 38 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/17 | 12/17 | | |
NCT03286751: A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants |
|
|
| Completed | 1 | 42 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 02/18 | 02/18 | | |
NCT03367390: A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) |
|
|
| Completed | 1 | 30 | US | AID System, LY8888AU, Insulin Lispro, LY275585 | Eli Lilly and Company | Type1 Diabetes Mellitus | 02/18 | 02/18 | | |
NCT03341312: A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM) |
|
|
| Completed | 1 | 36 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 03/18 | 03/18 | | |
NCT02623478: A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps |
|
|
| Withdrawn | 1 | 0 | NA | Insulin Lispro, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 04/18 | 04/18 | | |
NCT03341299: A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 36 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 04/18 | 04/18 | | |
NCT03407118: A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 31 | Japan | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585, Humalog | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 06/18 | 07/18 | | |
NCT03449433: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 80 | Europe | LY900014, Ultra-Rapid Lispro, Insulin Lispro, Humalog®, LY275585, Insulin Aspart, NovoRapid®, Fiasp® | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 08/18 | 08/18 | | |
NCT03170544: Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) |
|
|
| Completed | 1 | 69 | US | MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Humalog®, Placebo to glargine, Placebo to MK-1092, Dextrose, Glucose, Insulin | Merck Sharp & Dohme LLC | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 11/18 | 11/18 | | |
NCT03512236: A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 24 | Europe | BC Pram Ins, Symlin® and Humulin®, Humalog®, Placebo | Adocia | Type 1 Diabetes Mellitus | 02/19 | 02/19 | | |
NCT03916640: A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 24 | Europe | ADO09 formulation, Placebo, Symlin®, Humulin®, Humalog® | Adocia | Type 1 Diabetes Mellitus | 03/19 | 03/19 | | |
NCT04235439: PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males |
|
|
| Completed | 1 | 36 | Europe | Gan & Lee Insulin Lispro Injection, EU - approved Humalog ®, US - licensed Humalog ® | Gan and Lee Pharmaceuticals, USA | Diabetes Mellitus | 07/19 | 07/19 | | |
| Completed | 1 | 56 | Europe, Canada | LY900014, Ultra-Rapid Lispro, Insulin Lispro, Humalog, LY275585 | Eli Lilly and Company | Type 1 Diabetes Mellitus | 11/19 | 11/19 | | |
NCT04161976: A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 20 | Europe | LY900027, Insulin Lispro, Humalog, LY275585 | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 07/20 | 07/20 | | |
NCT04276207: A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps |
|
|
| Completed | 1 | 32 | Europe | LY900014, Insulin Lispro, Humalog, LY275585 | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 08/20 | 08/20 | | |
NCT04049123: A Study of LY900014 in Healthy Chinese Participants |
|
|
| Completed | 1 | 15 | RoW | LY900014, Ultra-Rapid Lispro, Insulin Lispro, LY275585, Humalog | Eli Lilly and Company | Healthy | 10/20 | 10/20 | | |
NCT04501107: A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 32 | Europe | Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1), Administration of Ready-to-use BioChaperone insulin lispro (IMP2), Administration of US-approved Humalog® (IMP3), Administration of EU-approved Humalog® (IMP4) | Adocia | Type 1 Diabetes | 11/20 | 11/20 | | |
NCT05067270: A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus |
|
|
| Completed | 1 | 40 | Europe | Sodium Citrate, Treprostinil, Humalog diluent, Magnesium Chloride | Eli Lilly and Company | Type 1 Diabetes Mellitus | 12/21 | 12/21 | | |
NCT05373199: A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes |
|
|
| Completed | 1 | 30 | Europe | Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Lantus®, Euglycemic clamp with Humalog® | Adocia, Tonghua Dongbao Pharmaceutical Co.,Ltd | Type 1 Diabetes | 10/22 | 10/22 | | |
NCT05262387: A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes |
|
|
| Completed | 1 | 25 | Canada | Lyumjev with 50% basal rate reduction, LY900014, Humalog with 50% basal rate reduction, Insulin Lispro, Humalog with 100% basal rate reduction, Lyumjev with 100% basal rate reduction | Eli Lilly and Company | Diabetes Mellitus, Type 1 | 03/23 | 03/23 | | |
